心型脂肪酸结合蛋白在肺疾病中的临床应用进展

Clinical Value of Heart Type Fatty Acid-binding Protein in Pulmonary Disease

心型脂肪酸结合蛋白(H-FABP)作为一种新生的生物学标志物近些年来获得研究者们的青睐,它是心肌损伤早期检测的标志物,具有高度特异性及敏感性。肺组织和肺血管疾病因并发右心功能不全而预后差,大部分患者死于右心衰竭。若临床早期发现肺疾病所致心肌受损,则有利于及早采取治疗措施,延缓病情进展。H-FABP可以作为所致肺疾病早期心肌损伤检测的标志物,用于评估病情危险程度及预后。本文就近年来H-FABP在急性肺栓塞(APE),慢性阻塞性肺疾病(COPD)、肺动脉高压(PH)、呼吸睡眠暂停(OSAHS)等疾病的临床应用进行综述。

The heart type fatty acid-binding protein （ H-FABP ） as a new biological marker receives closely attention in recent years. It characteristics of high specificity and strong sensitivity and has a value to screen early myocardial damage. When pulmonary parenchyma and pulmonary vascular disease involved right heart function, the prognosis is poor. Always, the majority of patients died from right heart failure. If we can early detect myocardial injury, we would take measures as soon as possible. H-FABP can be used as a marker of early myocardial damage caused by pulmonary disease. The detection of H-FABP can be help for assessment risk stratification and prognosis. In this paper, we reviewed the clinical value of H-FABP in acute pulmonary embolism （ APE ）, chronic obstructive pulmonary disease （ COPD ）, pulmonary hypertension （ PH ）, obstructive sleep apnea hypopnea syndrome （ OSAHS ） in recent years.